Industry Outlook

The global impetigo treatment market expected to reach US$ 1106.21 Mn by 2030 from US$ 579.59 Mn in 2021, growing at a CAGR of 7.3% during the forecast period from 2023 to 2030. Impetigo is a skin bacterial infection caused primarily by Staphylococcus aureus or Streptococcus pyogenes. These gram-positive bacteria infect the epidermal skin layer and cause highly contagious impetigo infection. The children are soft-targets for such pathogens and the infections with its huge prevalence in the areas with hot and humid climate. Depending on the causative agents, impetigo classification comprises non-bullous and bullous impetigo. Non-bullous impetigo is prevalent in 70% of the impetigo cases, accounts for around 10% of the all-cutaneous problems in pediatric clinics. It is primarily caused by Staphylococcus aureus or Streptococcus pyogenes or combination of both obverse to bullous form caused exclusively by S. aureus. The impetigo treatment majorly involves the infected wound care and prescription of topical or oral antibiotics.

The global impetigo treatment market is segmented based on the drug class for treatment into cephalosporins, fusidane, lincosamide, penicillin, penicillin-like antibiotics, pleuromutilin, pseudomonic acid A, quinolone, sulfonamides and folic acid inhibitors, and tetracyclines. The drug classes are available in topical agent or oral form, topical being predominantly prescribed due to effective results. The impetigo treatment market expected to surge during the forecast period owing to the growing incidence of the infection and development of novel therapeutics. However, the evolution of Methicillin-resistant S. aureus (MRSA) and macrolide-resistant Streptococcus is a major challenge to the treatment and forces manufacturer for the development of more efficient antibiotics, thereby contributing to the growth of the market. Thus, the impetigo treatment market provides enormous opportunities to the manufacturers as the impetigo incidence is rising and the healthcare infrastructure is growing in developing countries. 

"Penicillin & Penicillin-Like Antibiotics Expected to Drive the Market during the Forecast Period"

In 2021, penicillin and penicillin-like antibiotics together accounted for over 34% of the global impetigo treatment market. The two segments collectively expected to drive the global market. Antibiotics treatment is preferred to reduce the healing duration as most of the impetigo infections are resolved naturally. According to the Infectious Diseases Society of America, the impetigo should be treated with the topical antibiotics for 5 to 7 days such as pseudomonic acid A. Fusidic acid, another topical agent, is not available in the United States, however, physicians in Europe recommend fusidic acid or pseudomonic acid A as the first line of topical antibiotics. The market will surge during the forecast period owing to the development of novel drugs.

"North America will Continue to Retain its Dominance during the Forecast Period"

In 2021, North America led the global impetigo treatment market with around 34% of the market share, in terms of value. The United States dominated the North America market due to presence of healthcare infrastructure and high awareness regarding impetigo. The regional market will proliferate due to early drug approval in the United States that aids in early market capturing compared to rest of major economic regions. Europe follows North America, in terms of market value, due to high awareness of impetigo. Asia Pacific is the most lucrative market for impetigo due to the growing healthcare infrastructure and rising awareness of skin infections. Furthermore, the prime incidence of impetigo infections in hot and humid areas account for more infections in Asia Pacific, thereby accounting for the growth of the market.

"Focus on the Research and Development for Novel Drug Molecules expected to Fuel the Market"

With the growing usage of the antibiotics, the microorganisms are adapting to current antibiotics through genome modifications, which hinders the treatment pattern. Many studies had reported methicillin-resistant S aureus (MRSA) and macrolide-resistant Streptococcus earlier and current studies have reported fusidic acid resistant bacteria. The evolvement of these microbes burdens the manufacturers to develop effective treatment options, which expected to fuel the market growth. For instance, NovaBay Pharmaceuticals, Inc. is developing NVC-422 (topical agent) that is currently in phase II/III for impetigo treatment. The same molecule is in phase II for catheter infections. The product has performed well in early phases and expected to launch during the forecast period. Thus, the focus of manufacturer on the research and development for novel drug molecules expected to fuel the market. Key players in impetigo treatment market include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.

Along with the market quantification, the key qualitative market factors such as drivers, restraints and opportunities are also included in the report. Furthermore, the players are mapped based their business strength and product offering. Key players profiled in the report include GlaxoSmithKline plc, Karalex Pharma, LLC, Leo Pharma A/S, Lupin Limited, NovaBay Pharmaceuticals, Inc., Pfizer, Inc., Ranbaxy Laboratories Limited, Roche Holding AG, SANDOZ GmbH, Taro Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Impetigo Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Impetigo Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Impetigo Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Impetigo Treatment market?
• Which is the largest regional market for Impetigo Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Impetigo Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Impetigo Treatment market worldwide?